A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.

Autor: Zhang H; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, Tighiouart M, Shin HJ, Koenig L, Park W, Rycroft D, Nannapaneni S, Wang Y, Chen ZG, Shin DM
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2012 Aug 15; Vol. 131 (4), pp. 956-69. Date of Electronic Publication: 2011 Nov 19.
DOI: 10.1002/ijc.26427
Abstrakt: An antibody simultaneously targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), two major tumor growth-driving machineries, may provide a novel effective strategy for optimizing tumor targeting and maximizing potential clinical benefits. Human domain antibodies selected against VEGF and EGFR were formatted into a fully human dual-targeting IgG (DT-IgG) to directly target both antigens in a single molecule. We evaluated the efficacy of DT-IgG in comparison with bevacizumab and cetuximab alone and in combination in the lung cancer cell line A549 (low EGFR expression and KRAS mutant) and the head and neck squamous cell carcinoma (HNSCC) cell line Tu212 (high EGFR expression and KRAS wild type) in vitro and in vivo. DT-IgG suppressed Tu212 and A549 cell growth, inhibited EGFR activation and induced apoptosis as effectively as cetuximab, and neutralized VEGF as effectively as bevacizumab. DT-IgG induced EGFR-dependent VEGF internalization, constituting a novel antiangiogenesis mechanism. In xenograft models with lung and head and neck cancer cell lines, DT-IgG displayed efficacy equivalent to bevacizumab in diminishing tumor growth despite its short serum half-life (36 hr in rats) and both agents may constitute preferable alternatives to cetuximab in KRAS-mutant tumors. Immunofluorescence staining revealed that localization of DT-IgG was similar to that of cetuximab, largely associated with EGFR+tumor cells. Our proof of principle study suggests a DT-IgG against EGFR and VEGF as an alternative therapeutic strategy with potentially enhanced clinical benefit.
(Copyright © 2011 UICC.)
Databáze: MEDLINE
Externí odkaz: